# Innovent Biologics, Inc.

Type: Company (1801.HK)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/innovent-biologics-inc
Canonical HTML page: https://gethealthbrief.com/entity/innovent-biologics-inc

## Timeline

- **2026-08-25**: 2026 interim results and 2030 vision announced — Innovent announces strong H1 2026 growth and sets a new strategic goal to become a global premier biopharma.
- **2025**: Revenue surpasses RMB 10 billion — Innovent reports full-year revenue over RMB 10 billion and full-scale profitability.
- **2025**: Global partnership wave begins — Over the next ten months, Innovent reaches collaborations with Takeda, Eli Lilly, Pfizer, Ollin, and Spero.
- **2021**: Second transformation begins — Innovent moves from a long-term investment phase toward full profitability and scale.
- **2020**: Full value-chain capability established — Innovent completes the first transformation spanning R&D, manufacturing, and commercialization.
- **2016**: First transformation begins — Innovent starts shifting from an R&D-driven biotech into a biopharmaceutical company with full value-chain capabilities.

## Recent coverage (1 stories)

### Innovent Surpasses RMB10B Revenue, Eyes Global Healthcare Reach
2026-08-25 18:08:14 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Innovent's H1 2026 update signals a push from China regional champion to global biopharma with a 20+ asset partnered pipeline across oncology, autoimmune, cardiovascular/metabolic, and ophthalmology. Healthcare leaders should track how these global partnerships reshape care access and innovation.
Full story: https://gethealthbrief.com/story/innovent-2026-interim-global-healthcare

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.